{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-026070","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.694773+00:00","generated_at":"2026-05-26T04:50:14.020130+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Beam Therapeutics reports Q4 net loss of $90.4M; cash $850.7M, clinical milestones reaffirmed","bullets":["Net loss per share $1.09 in Q4 2024 vs net income of $1.77 in Q4 2023; full-year net loss $4.58 per share vs $1.72 in 2023.","Cash, equivalents and marketable securities $850.7M at Dec 31, 2024, expected to fund operations into 2027.","Adult enrollment target achieved in BEACON trial of BEAM-101; updated data and 30 patients dosed expected by mid-2025.","Initial data from BEAM-302 Phase 1/2 in alpha-1 antitrypsin deficiency expected in H1 2025; BEAM-301 dosing to start early 2025.","Appointed Sravan Emany as CFO; Chirfi Guindo to board; IND-enabling studies for ESCAPE conditioning ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-026070","json":"https://secwatch.observer/filing/0000950170-25-026070.json","markdown":"https://secwatch.observer/filing/0000950170-25-026070.md","text":"https://secwatch.observer/filing/0000950170-25-026070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025026070/0000950170-25-026070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025026070/beam-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:50:14.020130+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}